تجاوز إلى المحتوى الرئيسي
عنوان الدراسة الجهاز رقم البروتوكول الراعي الحالة موقع الدراسة
A phase IIIb, open, multi-country, controlled, randomized study to demonstrate the immunogenicity and safety of GSK Biological meningococcal conjugate vaccine, MenACWYTT (GSK134612) in healthy infants, given on a 3+1 primary and booster (2, 4, 6 and 15-1 114858




GSK




مرفوض N\A
An observational study to evaluate caregiver's preference and treatment outcome in patient with alzheimer's disease treated with oral or tramsdermal monotheraby - Real-World Evaluation of compliance and preference in the treatment of Alzheimer's disease( CENA713D-MAX-SA-01 Novartis جاري Dr. Soliman Fakeeh Hospital (Jeddah)
Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) When Exposed to Plasma-derived Von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVI ABB- 09 -001 King Faisal Specialist Hospital & Research Centere جاري King Faisal Specialist Hospital and Research Center (Riyadh)
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor in de novo renal transplantation - Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRoli CRAD001A2433 Novartis جاري Prince Sultan Military Medical City (Riyadh)
(FLASH study)A 12-week treatment, multi-center, randomized, doubleblind,double-dummy, parallel group study to assess the efficacy and safety of switching fromsalmeterol/fluticasone to QVA149 (indacaterolmaleate/glycopyrronium bromide) in symptomatic COPD A3405 V01 Novartis جاري King Fahad Medical City (Riyadh)
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial BAY 63-2521 / 13605 Bayer مكتمل King Fahad Medical City (Riyadh)
A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [Saf MO28048 Roche جاري King Faisal Specialist Hospital and Research Center (Jeddah)
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Dis MST-188-01 Mast Therapeutics جاري King Khalid University Hospital (Riyadh)
A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor pos CLEE011E2301 Novartis جاري King Khalid University Hospital (Riyadh)
AWARE-AMAC (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation in Asia pacific, Middle-east and African Countries (AWARE-AMAC): A noninterventional study to collect data on the management and clinical impacts of chronic urticaria E3401 Novartis جاري King Abdulaziz University Hospital (Jeddah)
عرض 61 - 70 من 118